The WACC of Dishman Carbogen Amcis Ltd (DCAL.NS) is 11.7%.
Range | Selected | |
Cost of equity | 12.2% - 16.5% | 14.35% |
Tax rate | 30.0% - 30.0% | 30% |
Cost of debt | 4.0% - 18.6% | 11.3% |
WACC | 8.4% - 15.1% | 11.7% |
Category | Low | High |
Long-term bond rate | 6.9% | 7.4% |
Equity market risk premium | 8.3% | 9.3% |
Adjusted beta | 0.64 | 0.92 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 12.2% | 16.5% |
Tax rate | 30.0% | 30.0% |
Debt/Equity ratio | 0.69 | 0.69 |
Cost of debt | 4.0% | 18.6% |
After-tax WACC | 8.4% | 15.1% |
Selected WACC | 11.7% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
DCAL.NS | Dishman Carbogen Amcis Ltd | 0.69 | 1.23 | 0.83 |
043090.KQ | Cube&Company Co Ltd | 2.66 | -0.63 | -0.22 |
087010.KQ | Peptron Inc | 0 | -0.19 | -0.19 |
206650.KQ | EuBiologics Co Ltd | 0.03 | 0.2 | 0.2 |
526853.BO | Bilcare Ltd | 4.08 | 1.46 | 0.38 |
539267.BO | Dr Habeebullah Life Sciences Ltd | 0.07 | 0.22 | 0.21 |
6118.HK | Austar Lifesciences Ltd | 1.15 | 0.85 | 0.47 |
BROOKS.NS | Brooks Laboratories Ltd | 0.01 | 1.2 | 1.19 |
DIVISLAB.NS | Divi's Laboratories Ltd | 0 | 0.78 | 0.78 |
SUVEN.NS | Suven Life Sciences Ltd | 0 | 1.41 | 1.41 |
Low | High | |
Unlevered beta | 0.31 | 0.6 |
Relevered beta | 0.46 | 0.88 |
Adjusted relevered beta | 0.64 | 0.92 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for DCAL.NS:
cost_of_equity (14.35%) = risk_free_rate (7.15%) + equity_risk_premium (8.80%) * adjusted_beta (0.64) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.